Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors |
December 12, 2018 | December 2018 Bond Updates |
- Roche collaborates with Merck to develop companion diagnostic for use with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in advanced solid tumors with mismatch repair deficiency (dMMR) - Roche will seek FDA approval for biomarker panel expected to provide a standardized... |
View more at: https://www.prnewswire.com:443/news-releases/roche-to-develop-companion-diagnostic-test-to-help-identify-patients-eligible-for-anti-pd-1-therapy-based-on-biomarker-expression-not-location-of-solid-tumors-853401913.html |
Related News |
|